Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The aim of this single-center prospective study is to evaluate the efficacy and feasibility
of Metoprolol, a beta-blocker, in the treatment of cytokine release syndrome (CRS) caused by
Chimeric antigen receptor T (CART) cells, to verify its effects on decreasing the level of
Interleukin-6 (IL-6), and to determine whether it can replace the intervention of other
antibodies, such as tocilizumab.